Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
about
Bending the Cost Curve in Cancer CareAntibiotics for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationPrimary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patientsAntibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationAntibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapyQ24235340Antibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationGranulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphomaAntibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationProphylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapyAntibiotics plus colony stimulating factors versus CSFs alone and antibiotics plus CSFs versus no prophylaxis for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationBiosimilars in the management of neutropenia: focus on filgrastimThe importance of the granulocyte-colony stimulating factor in oncologyHematopoietic growth factors: personalization of risks and benefitsDesign Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating FactorThe impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trialsManagement of neutropenic patients in the intensive care unit (NEWBORNS EXCLUDED) recommendations from an expert panel from the French Intensive Care Society (SRLF) with the French Group for Pediatric Intensive Care Emergencies (GFRUP), the French STherapy-related myeloid neoplasms: pathobiology and clinical characteristicsProphylactic Measures During Induction for Acute Myeloid Leukemia.Predicting neutropenia risk in patients with cancer using electronic data.Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.Filgrastim improves survival in lethally irradiated nonhuman primatesRisk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study.Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?How we treat febrile neutropenia in patients receiving cancer chemotherapyInhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitorsPharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trialPredicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysisRetrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer.Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trialsTreatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Treatment of cancer in the older aged person.Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice.Incidence and impact of baseline electrolyte abnormalities in patients admitted with chemotherapy induced febrile neutropenia.
P2860
Q22248106-2301AD83-07CF-4EB5-8B52-8D32BC6E0A81Q24186282-750DCD22-0B63-4ECE-B03D-A94741067BDBQ24198118-AE4E2E2E-8ACD-468E-AF29-28DFCAD0FAC6Q24200225-2500539B-111F-4EA8-920A-3613AAA5F704Q24203869-0FE34BF8-FE90-4D35-9CE6-F89349FCD3DCQ24235340-824C1F98-E37F-4E62-8E70-5AFA40CE1C69Q24235345-66E3846A-EFC1-4119-855E-C9BF4283CFB3Q24240753-817FBBD2-5F4E-4794-9893-340398D71CE9Q24241475-2A9A5A51-00D1-4F72-B4EB-0484803FE3B3Q24241680-F8C58BD4-05FE-447B-8371-A8B5668E0C4DQ24241689-03921BD6-3134-4EE7-BD10-AAE7060576F9Q26764906-64FE9B0A-F9B8-4207-83C0-D365351EA393Q26770908-3E232C04-54BA-4C7A-B4BE-FB900CCA35CBQ26866922-56DA20D7-D6B6-4988-8450-A0BEC3C8D15EQ27004054-5841CBDF-54A4-4997-8ADA-C04FA5C45556Q27008080-CD300C33-C103-4184-9AD5-263CD0DFB07BQ27320711-51E7CBC3-349D-4142-A2F1-1D774041F9CCQ28386366-B0944FFF-FB9B-4DC7-B292-F4067E945229Q30235496-084DD647-1620-4A88-A4C1-AE0D505A7202Q31131362-14502DEE-8096-43CA-AADB-954760C67D90Q33385774-3A16A421-E9BE-4F81-A862-15F6979ABE38Q33390547-4A94C4EA-D915-49D1-B6B7-68B399CC6900Q33543823-7F27FCE0-7D5C-4DD2-8BF5-A57BD68B37BDQ33599892-9484D4C4-611C-4595-9F97-25040C57F403Q33752272-F6AF9076-D4F2-4789-83A6-E4BAFBE946ABQ33756369-E0BDAAAC-1A77-4D81-8B3A-BD0CC0414E74Q33846201-934788C3-A711-42BD-AA76-AF29AC26CE1FQ33903025-FB6171D2-6E9C-4B3A-B7C0-BAA499363F7EQ33926132-671A0ECF-C279-4FDE-B09E-B99B70A6BBE5Q34013208-57880C6F-BDDE-47CF-ADE7-BE5F326A3F5BQ34026627-927612F4-4560-41E0-AFEC-5A7FB371CB54Q34029496-CBE575AD-2D1A-4BE2-ACAC-DA86E4F395F9Q34071621-9FAA4893-6955-442A-A751-D47FD814521CQ34184798-DEE429F7-CFFF-4C26-AA47-49ED3245BA78Q34352408-FB4AC721-7BDE-493B-920A-D134282501C3Q34374754-AA871E1E-D3E6-47B6-8B8B-626004FFED3DQ34532546-47F3BF9F-4E33-4251-A3A7-963A53090121Q34549328-F257BA80-2D98-4176-8D20-BF2ADE578BADQ34553998-58D6663B-A558-4560-BEC7-C19A408976FFQ34575183-6CA92150-19DF-44DB-9AA4-45B26711A509
P2860
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Impact of primary prophylaxis ...... otherapy: a systematic review.
@en
type
label
Impact of primary prophylaxis ...... otherapy: a systematic review.
@en
prefLabel
Impact of primary prophylaxis ...... otherapy: a systematic review.
@en
P2093
P356
P1476
Impact of primary prophylaxis ...... otherapy: a systematic review.
@en
P2093
David C Dale
Gary H Lyman
Jeffrey Crawford
Nicole M Kuderer
P304
P356
10.1200/JCO.2006.08.8823
P407
P577
2007-07-01T00:00:00Z